19 August 2021
Welcome to this week’s edition of Stock Take, Stockfox’s weekly share market update. For our New Zealand readers, we hope you and your loved ones are managing okay during the Level 4 Covid-19 restrictions.
As always, the share markets never let up. So read on to find out what’s been going on and what’s new with Stockfox.
This graph of the US stock market (green line), the Australian market (blue line) and the NZ market (purple line) shows a disturbing trend.
While the US and Australian markets have been moving steadily upwards in the past six months, the NZ market has gone exactly nowhere. This suggests the boost that came last year from NZ being less affected by Covid-19 than other western countries is no longer being felt and, if anything, international capital is flowing out of NZ to the other markets.
We encourage investors to increase their exposure to the Australian and US markets because those countries’ deeper pockets should ensure more extended quantitative easing measures.
Tip of the week
This week’s tip of the week is for a NASDAQ-listed biopharmaceutical company focused on the discovery, development and commercialisation of new medicine for people with cancer. The company’s share price has recovered after some disappointing liver study results, and its recent Q2 financial results have beaten expectations. The company currently seems undervalued and has good growth prospects.
Read the tip here.
See the results of our best performing NZX tips over the past three months.
See the performance of all Stockfox tips here.